Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis

Abstract Background Eplerenone and spironolactone, recognized as mineralocorticoid receptor antagonists (MRAs), have been reported to improve clinical prognosis among individuals diagnosed with heart failure (HF). However, the difference in the clinical effects between eplerenone and spironolactone...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ahmed Elshahat, Ahmed Mansour, Mohamed Ellabban, Ahmed Diaa, Atef Hassan, Ahmed Fawzy, Omar Abdulrahman Saad, Moaz Abouelmagd, Mahmoud Eid, Ahmed Elaraby, Mohamed Hamouda Elkasaby, Ahmed Abdelaziz
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2024-09-01
Edice:	BMC Cardiovascular Disorders
Témata:	Mineralocorticoid receptor antagonist MRA Eplerenone Spironolactone Heart failure
On-line přístup:	https://doi.org/10.1186/s12872-024-04103-7
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!